Genmab — Januar 2021
-
Amivantamab presentation
https://www.oncologysciencehub.com/wclc2020/ -
thx EL - nice looking ORR and counting stable disease very impressive indeed
-
"Sabari was confident enough in amivantamab’s data to take a swipe at mobocertinib, saying the Takeda program matched up poorly on safety given Thursday’s results" https://endpts.com/jj-pushes-new-amivantamab-data-for-nsclc-subset-trying-to-bolster-case-for-quick-fda-approval/
-
comments from Joshua Bauml, MD
@Jbauml -
have you guys been drinking again
-
by the way, that fierce biotech article said 'Though J&J may snag the first approval for this patient population, its drug is given through intravenous infusion, which could give mobocertinib, an oral drug, an advantage on the convenience side.' But we know Amivantamab is being tried in Subcutaneous form as well
-
we can only hope people are catching up to the fact, that it is a grant of warrants and not an exercise.
-
@E L 09:17, Seems like people finally understand that ownership in the company by the employees far outweigh the “negative” consequence of the increase in number of shares outstanding for the private investor. Took quite some time, but better late than never lol.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind